Cargando…

Tackling Nonatrial Fibrillation Diseases Using Nonvitamin K Antagonist Oral Anticoagulant: by What and for Whom?

Detalles Bibliográficos
Autor principal:	Kim, Jong S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Stroke Society 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780012/ https://www.ncbi.nlm.nih.gov/pubmed/31590470 http://dx.doi.org/10.5853/jos.2019.02474

Ejemplares similares

Nonvitamin K antagonist oral anticoagulants (NOACs): the tide continues to come in
por: Blann, Andrew
Publicado: (2015)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Tooth extraction in patients taking nonvitamin K antagonist oral anticoagulants
por: Morimoto, Yoshinari, et al.
Publicado: (2016)

Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment
por: Turpie, Alexander G.G., et al.
Publicado: (2017)

The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation
por: Beyer-Westendorf, Jan, et al.
Publicado: (2021)

Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants
por: Sarah, Lessire, et al.
Publicado: (2014)

Erratum to “Preventive Strategies against Bleeding due to Nonvitamin K Antagonist Oral Anticoagulants”
por: Lessire, Sarah, et al.
Publicado: (2014)

Real‐world use of nonvitamin K antagonist oral anticoagulant in atrial fibrillation patients with liver disease: A meta‐analysis
por: Dai, Qixin, et al.
Publicado: (2020)

The change of renal functions after nonvitamin K oral anticoagulants in patients with atrial fibrillation
por: Chantrarat, Thoranis, et al.
Publicado: (2021)

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
por: Gallù, Mariacarla, et al.
Publicado: (2020)

Patient Preferences for Nonvitamin K Antagonist Oral Anticoagulants in Stroke Prevention: A Multicountry Discrete Choice Experiment
por: Wilke, Thomas, et al.
Publicado: (2019)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
por: Søgaard, Mette, et al.
Publicado: (2019)

Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
por: Mustanoja, Satu, et al.
Publicado: (2015)

Impact of Reduced-Dose Nonvitamin K Antagonist Oral Anticoagulants on Outcomes Compared to Warfarin in Korean Patients with Atrial Fibrillation: A Nationwide Population-Based Study
por: Han, Sola, et al.
Publicado: (2021)

A Comparison among Nonvitamin K Antagonist Oral Anticoagulants in Asian Patients with Venous Thromboembolism: A Multi-Institutional Study
por: Tsai, Ming-Lung, et al.
Publicado: (2022)

Difference between the Upper and the Lower Gastrointestinal Bleeding in Patients Taking Nonvitamin K Oral Anticoagulants
por: Maruyama, Kyohei, et al.
Publicado: (2018)

Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
por: Chaiyana, Parata, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects
por: Parasrampuria, Dolly A., et al.
Publicado: (2015)

Optimal nonvitamin K antagonist oral anticoagulant therapy in a warfarin-sensitive patient after left atrial appendage closure: A case report
por: Shen, Long, et al.
Publicado: (2018)

Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS(2) score ⩾ 2
por: Fernandez, Maria M, et al.
Publicado: (2015)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Breaking bad: Higher risk of osteoporosis with vitamin K antagonists compared to direct oral anticoagulants in patients with atrial fibrillation
por: Fender, Anke C., et al.
Publicado: (2020)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
por: Wu, Olivia, et al.
Publicado: (2022)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Clinical outcomes of nonvitamin K oral anticoagulants and acenocoumarol for stroke prevention in contemporary practice: A population‐based propensity‐weighted cohort study
por: Rodríguez‐Bernal, Clara L., et al.
Publicado: (2020)

Variability in Nonvitamin K Oral Anticoagulant Dose Eligibility and Adjustment According to Renal Formulae and Clinical Outcomes in Patients With Atrial Fibrillation With and Without Chronic Kidney Disease: Insights From ORBIT‐AF II
por: Yao, Ren Jie Robert, et al.
Publicado: (2023)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Outcomes of 4-factor Prothrombin Complex Concentrate in Patients With Liver Disease and Nonvitamin K Antagonist-Related Coagulopathy: A Retrospective Study
por: Dodhiawala, Paarth B., et al.
Publicado: (2023)

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer
por: Kim, Kyu, et al.
Publicado: (2018)

Disentangling what works best for whom in comorbidity
por: Glozier, Nick, et al.
Publicado: (2022)

Oral Anticoagulants for Atrial Fibrillation Patients with Active Cancer
por: Kim, Do Young, et al.
Publicado: (2018)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis
por: Santarpia, Giuseppe, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t7h8n5ruvn9pbkg2ld6dlt94i7